Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children*
- 1 December 2003
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (12) , 2788-2793
- https://doi.org/10.1097/01.ccm.0000100122.57249.5d
Abstract
Meningococcal sepsis invariably is associated with coagulopathy. We have previously reported an association between mortality rate in meningococcal disease and the functional 4G/5G promoter polymorphism of the plasminogen-activator-inhibitor (PAI)-1 gene in a small patient cohort. In a much larger cohort, we aimed to confirm these results and further investigate the role of the 4G/5G polymorphism in determining susceptibility, outcome, and complications of disease.DESIGN Susceptibility was investigated in two separate studies, a case-control study and a family-based transmission study, each test using a separate patient cohort. Severity was investigated using clinical diagnosis, the presence of vascular complications, Pediatric Risk of Mortality (PRISM)-predicted morality, and actual mortality.University hospital and laboratories.Subjects were 510 UK pediatric patients, 210 parents of patients, and 155 UK Caucasian controls.DNA extraction and 4G/5G PAI-1 genotyping was carried out using published techniques.Predicted mortality distribution differed significantly between genotypes (p =.05) with a significantly higher median PRISM in the 4G/4G (41.1%) than the 4G/5G (23.4%) and 5G/5G (19.0%) genotyped patients combined (p =.02). Actual mortality rate was significantly associated with both genotype (chi-square = 14.8, p =.001) and allele frequencies (chi-square = 14.0, p <.0001), with more deaths in the 4G/4G (28.4%) than the 4G/5G and 5G/5G genotyped patients combined (14.9%; chi-square = 7.9; p =.005; risk ratio, 1.9; 95% confidence interval, 1.2-3.0). Logistic regression indicated a 40% and 91% reduction in the odds of dying if a patient was either 4G/5G or 5G/5G, respectively, in comparison to a 4G homozygous patient. When analyzed by clinical diagnosis, the association with death was found only in the sepsis group (chi-square = 18.7, p <.0001; risk ratio, 2.7; 95% confidence interval, 1.6-4.6). In survivors of disease, a significantly higher proportion of 4G/4G patients suffered from vascular complications (chi-square = 6.7, p =.03; risk ratio, 2.4; 95% confidence interval, 1.1-5.0). The 4G/5G polymorphism was not associated or linked with susceptibility (case-control result, p =.6; family-based transmission study results, p =.2).This study confirms that Caucasian pediatric patients carrying the functional PAI-1 4G/4G genotype are at an increased risk of developing vascular complications and dying from meningococcal disease.Keywords
This publication has 44 references indexed in Scilit:
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- PAI‐1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organsAmerican Journal of Hematology, 2002
- Proposed guidelines for papers describing DNA polymorphism-disease associationsHuman Genetics, 2002
- Dysfunction of Endothelial Protein C Activation in Severe Meningococcal SepsisNew England Journal of Medicine, 2001
- Comparison of the performance of two general and three specific scoring systems for meningococcal septic shock in childrenCritical Care Medicine, 2000
- Book Review Comprehensive Clinical Nephrology By Richard J. Johnson and John Feehally. Approximately 700 pp., illustrated. St. Louis, Mosby, 2000. $189. 0-7234-3117-5New England Journal of Medicine, 2000
- Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Protein S and C alterations in acutely III patientsAmerican Journal of Hematology, 1991
- Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal SubjectsNew England Journal of Medicine, 1989
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985